Boehringer Ingelheim

II

1280-0022 Xenera-1: A multi-centre, double-blind, placebo-controlled,randomised phase II trial to compare efficacy of xentuzumab incombination with everolimus and exemestane versus everolimus andexemestane in post-menopausal women with HR+ / HER2-metastatic breast cancer and non-visceral disease

Breast

Constellation

1b/2

ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule
Inhibitor of EZH2, Combined with Enzalutamide or
Abiraterone/Prednisone in Patients with Metastatic Castration
Resistant Prostate Cancer

Prostate

G1 Therapeutics

I

G1 Therapeutics G1T48-01: A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability,Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 inWomen with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Breast

Mirati Therapeutics, Inc.

II

A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

Lung

Novartis

II

A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2- negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment (BYLieve)

Breast

Pfizer

III

Pfizer C3441021 – TALAPRO: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDYOF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATICCASTRATION-RESISTANT PROSTATE CANCER

Prostate

Mirati Therapeutics, Inc.

III

Mirati: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

NSCLC

Jounce

II

Jounce : Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb)JTX-2011 and a CTLA-4 inhibitor in PD-1/PD-L1 Inhibitor ExperiencedAdult Subjects with Non-small Cell Lung Cancer or Urothelial Cancer

NSCLC & Urothelial

Novartis

III

Novartis Canopy A: A phase III, multicenter, randomized, double blind, placebocontrolledstudy evaluating the efficacy and safety ofcanakinumab versus placebo as adjuvant therapy in adultsubjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cmN2) completely resected (R0) non-small cell lung cancer(NSCLC)

NSCLC

GSK

IB

GSK: A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrate-resistant prostate cancer (CRPC):

Prostate

Carrick

I/II

Carrick Therapeutics: CT7001_002: A Phase 1/2 Study of CT7001 in Combination with Fulvestrant in Patients with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer:

Breast

Boehringer Ingelheim

Ib

Boehringer Ingelheim – 1336-0011 – 6 cohorts Basket: An open label phase Ib dose finding study of BI 836880 in combination with BI 754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors:

NSCLC, SCLC, GBM, Melanoma, Hepatocellular

Immunomedics, Inc

II

A PHASE 2 OPEN LABEL STUDY OF SACITUZUMABGOVITECAN (IMMU-132) IN SUBJECTS WITHMETASTATIC SOLID TUMORS:

NSCLC, HNSCC, Endometrial Cancer

Mirati Therapeutics, Inc.

I/II

Mirati phase 1/2 (Basket) – A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation:

Advanced Solid Tumors

Lilly

I/II

Lilly: J2K-MC-JZKA: A Phase 1/2 Study of LY3499446 Administered to Patients with AdvancedSolid Tumors with KRAS G12C mutation:

Advanced Solid Tumors

Amgen Inc.

III

Amgen: AMG 510: 20190009: A Phase 3 Multicenter, Randomized, OpenLabel, Active-controlled, Study of AMG 510Versus Docetaxel for the Treatment of previouslytreated Locally Advanced and unresectable orMetastatic NSCLC Subjects with Mutated KRASp.G12C:

NSCLC

Bayer

Ib/2

Bayer : An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors:

Advanced Solid Tumors

Jiangsu Hengrui Medicine Co., Ltd.

III

A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy:

Advanced Hepatocellular Carcinoma

EMD Serono/Merck

II/III

(MS200647_0055): A Phase II/III, Multicenter, Randomized,Placebo-controlled Study of Gemcitabine PlusCisplatin With or Without M7824 (bintrafusp alfa)as First-line Treatment of Biliary Tract Cancer:

Biliary Tract Cancer

Pfizer

I

Pfizer: (EZH2): 235999: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITHRELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULARLYMPHOMA (FL):

SCLC, Prostate, Follicular Lymphoma

Astellas

II

Astellas: An Open-Label, Multicenter, Multi-Cohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202):

Breast HR+/HER2-, TNBC, SQNSCLC, NSCLC, H&N Cancer, Gastric/Esophageal Cancer

Genentech

III

Genentech: WO41554: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER:

Breast

DIZAL PHARMA

I/II

DZ2019ER001 Study for Breast Cancer: A Phase I/II, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of DZD3969 as Monotherapy or in combination with Palbociclib in Postmenopausal Female Patients with Estrogen Receptor Positive (ER+) and HER2 Negative (HER2-) Breast Cancer:

Breast

Pfizer

IB

Pfizer C3651009: A PHASE 1B, 12-WEEK, OPEN-LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING REPEATED SUBCUTANEOUS ADMINISTRATIONS OF PF 06946860 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND CACHEXIA:

NSCLC & Cachexia

Morphosys

II/III

A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)

Novocure

Device

LUNAR: Pivotal, randomized, open-label study of Tumor Treating Fields
(TTFields) concurrent with standard of care therapies for treatment of stage 4
non-small cell lung cancer (NSCLC) following platinum failure

NSCLC